European and U.S. agencies approve a third amyloid PET tracer, florbetaben.
The overused adage of the fountain of youth rears its head again, as four new studies show how young blood rejuvenates old brain and muscle, pumping up the vasculature, stem cells, and restoring microglia’s appetite for waste products. Researcher are isolating the responsible factors, for example GDF11.
A gene already well known to counteract aging appears to improve cognition.
Known for helping form new memories, new neurons may be just as important for erasing old ones.
Resveratrol consumption failed to correlate with heart disease, inflammation, cancer, or even mortality in a community-based study. Are its benefits overstated?
New NIH policies will require researchers to study male and female biology.
Will an antibody signature make for a new Alzheimer’s diagnostic?
Mesulam Awarded Potamkin Prize Three’s Company: Florbetaben Approved, Excludes AD Diagnosis PET Tracers Enlighten at Neurology Conference Blood Patterns: Prowling for Alzheimer’s Clues in Plasma Tau imaging of patients with different kinds of dementia and ...
By paring back calcium signaling, researchers prevented signs of Alzheimer’s in mice carrying a presenilin mutation. Could the strategy work in humans?
MetLife rewards research on secretases, toxic Aβ transmission.
New twist to fluorescence-based microscopy lets scientists see up-close how Aβ aggregates in living cells.
A candidate reference method for measuring Aβ42 in cerebrospinal fluid brings researchers closer to standardization.
Playing nursemaid, TGF-β helps new neurons in the brain survive, develop, and migrate.
In award-winning documentary, son traces his mother’s progression into Alzheimer’s disease.
Combination Drug Trials: Time to Open a New Front in AD? Combination Trials: FDA Puts Flesh on Bones of Draft Guidance Combination Trials: Companies Can Play Well in One Sandbox Building a Roadmap for Shared Combination Drug Trials ACT-AD FDA/AD Allies ...